10x Genomics

Phase A — Understand the business

Lens 1 · Company Overview

Business model — razor/blade in life-science research tools. 10x is a life-sciences technology company headquartered in Pleasanton, CA, incorporated in Delaware in 2012, commercial since 2015. It builds "integrated research solutions" — an instrument + its proprietary consumables + bundled software — that let researchers interrogate biology at single-cell resolution and at spatial (tissue-map) resolution. Two product families:

• Single Cell — the Chromium instrument line (the original franchise; droplet microfluidics).
• Spatial — Visium CytAssist and the Xenium Analyzer (in-situ, sub-cellular spatial transcriptomics), plus the newly launched Atera whole-transcriptome spatial platform.

The economics are in the blade. FY2025: instruments were only $56.8M of revenue and fell 39%; consumables were $507.2M and grew 3%; services $32.7M. So ~85% of product revenue is recurring consumable pull-through from an installed base of 8,046 cumulative instruments sold since 2015 (1,007 placed in 2025, down from 1,073 in 2024) consuming 424,000 reactions in 2025 (up from 357,100). The installed base is the annuity; instrument placements are the leading indicator of future consumable growth — which is why a 39% instrument decline is the bear's favorite chart even as consumables grow.

Customers / suppliers / structure. Customers are academic and translational researchers and biopharma, globally — no single customer >10% of revenue in 2025/2024/2023 (genuinely diversified demand). Payment terms are plain-vanilla: invoiced on shipment, net-30, no rights of return, no significant financing component — not take-or-pay, not long-dated contracts. The "contract" that matters is scientific lock-in: >10,000 peer-reviewed papers cite 10x data, and publication is the adoption flywheel.

Lens 2 · Supply Chain

Map: custom oligos + enzymes (single-sourced specialty suppliers) → 10x in-house consumables manufacturing (Pleasanton) + outsourced instrument assembly → distributors / direct sales → academic & biopharma labs.

• Upstream inputs. Reagent kits depend on "several suppliers for key components"; certain raw materials — oligonucleotides and enzymes — are custom-manufactured by outside partners. This is the genuine chokepoint: specialty-oligo and enzyme supply is concentrated and qualification is slow.
• Manufacturing — the moat node. The majority of consumables (gel-bead generation, surfactant synthesis, emulsion-oil formulation, reagent formulation, certain microfluidic chips, kit assembly) are made in-house at Pleasanton — this vertical integration is what protects the 69-70% gross margin. Instruments are outsourced to ISO-13485 contract manufacturers in Asia and the US; 10x does only optical + final assembly + test of Xenium in-house.
• Single physical chokepoint. Pleasanton sits near earthquake fault zones; "substantially all" long-lived assets are in the US — a single-site consumables manufacturing concentration risk.
• Downstream. Sells direct and via third-party distributors across Asia, Europe, Oceania, North/South America, the Middle East and Africa; distributor inventory has whipsawed before (China distributors held excess inventory post-COVID, depressing 2023 sell-in). ~27% of sales are non-USD (principally euro).

Named-stakeholder note: the filings name categories (oligo/enzyme partners, Asian contract manufacturers) rather than specific vendor names; Macrogen / Psomagen are named on the demand side as the first service-provider committing to deploy multiple Atera units.

Lens 3 · Competitive Advantages (moats)

Moat verdict: a real but contested IP-and-installed-base moat, narrower than the bull case and actively under assault on its newest flank (spatial).

1. Installed base + consumable lock-in (the durable moat). 8,046 instruments in the field generating recurring, switching-cost-protected consumable revenue. Once a lab standardizes a Chromium/Xenium workflow and publishes on it, re-validating a rival platform is costly and slow — the publication-as-best-practice dynamic is a genuine network effect.
2. Vertical-integrated consumables manufacturing → 70% gross margin. In-housing the chips/reagents is a process moat that few startups can replicate at scale.
3. Patent estate (the moat 10x enforces — see Lens 10). 10x is the industry's most aggressive IP litigant; it has used patents to win injunctions (UPC permanent injunction against Curio in Germany/France/Sweden; consent judgment + injunction against Parse on ATAC-seq). The estate is real bargaining power.
4. Bargaining power. Over customers: moderate — diversified, no >10% customer, but customers are budget-constrained academics with NIH-funding sensitivity, so 10x has limited pricing power right now (instrument price decreases drove part of the 2025 instrument revenue drop). Over suppliers: weak on single-sourced oligos/enzymes; strong on commoditized inputs.

Where the moat is cracking: the single-cell IP wins are partly being unwound at the PTAB (three 10x patents found unpatentable in IPR, Feb 2025, now on appeal), and Illumina — a far larger, far better-capitalized rival — is entering spatial directly, with a platform 10x claims has "9x larger capture area and 4x greater resolution" framing. A moat you have to defend in five simultaneous courtrooms is a moat with a hole in it.

Lens 4 · Segments

10x reports one reportable segment ("integrated research solutions") — the CODM (the CEO) runs it consolidated. So the meaningful cuts are by product line and by geography, both fully sourced.

By product line (the story of the whole dossier):

[All rows research-layer: filings/10-k-2025-q4.md and filings/10-q-2026-q1.md]

Trend read: the cause of the headline weakness is (a) collapsing instrument placements (price cuts + budget-constrained labs deferring capex) and (b) the roll-off of one-time settlement revenue. The cause of the underlying strength is spatial consumables compounding ~20-31% as the Xenium installed base matures into pull-through, plus Single Cell consumables re-accelerating to +6% in Q1 2026 after a flat-to-down 2025 — the single-cell franchise stabilizing is the most underappreciated line in the table.

By geography (Q1 2026, location of customer):

Geographic read: the US decline (−12%) is the NIH/academic-funding-pressure story made visible — but note US Q1'25 included the $16.8M Vizgen license, so ex-settlement the US core was roughly flat-to-down on real research budgets. EMEA (+16%) and Asia-Pacific ex-China (+16%) are carrying the franchise while US academic funding is soft and China is in structural decline (−6%, on top of years of distributor de-stocking).

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print — Q1 2026, reported 2026-05-07)

The cleanest possible "beat-and-fade."

• Revenue $150.8M, −3% reported but +9% on core products/services — beat consensus by ~3.6%. The reported decline is entirely the $16.1M settlement-revenue roll-off.
• Drivers: consumables +13% ($129.8M), spatial consumables +31%, single-cell consumables +6%; instruments −24% (the soft spot).
• Margins: gross margin 70% (up from 68%), helped by lower inventory write-downs (−$9.2M) and lower warranty costs. Operating loss narrowed to $(17.0)M from $(39.3)M; net loss $(13.5)M ($(0.10)/sh) vs $(34.4)M ($(0.28)/sh).
• Opex discipline is the real story under the hood: SG&A −26% to $66.4M (legal spend rolling off as settlements close), R&D −12% to $56.8M; total opex −15%.
• Guidance: FY2026 revenue reaffirmed at $600–625M = 0-4% growth ex-settlements; management explicitly guided Q2 and Q3 to step down sequentially on Atera-related purchasing delays (customers pausing Xenium buys ahead of the new platform).
• Balance-sheet flags (all green): cash + marketable securities $509.8M, zero debt. Inventory down to $53.5M (from $56.3M) — healthy, no channel stuffing. Accrued bonus drained from $29.5M to $7.9M (normal Q1 payout).
• Market reaction: stock FELL 5.3–8.2% despite the beat. What the tape priced: the market doesn't care about the Q1 beat; it cares that Q2/Q3 guide down and that the new $495K Atera may cannibalize the very Xenium pull-through that's working. A beat that sells off is the market telling you expectations had already run ahead of the print — consistent with a +73% YTD move into the quarter.

Unusual vs. own history: FY2025 generated $136.1M operating cash flow (vs $6.7M in 2024) — the first time the cash engine looks real, but inflated by $60M of settlement cash (Vizgen $26M + two Bruker installments $34M) collected in-period. Ex-settlement OCF is far thinner — a flag the cash-flow strength is partly non-recurring.

Lens 6 · Earnings Calls (sentiment trend)

Transcripts were not on the research-layer shelf (transcripts=0), so this lens is ``-grounded from the Q1 2026 call coverage.

• Management focus (Q1 2026): the Atera launch as a "pivotal" answer to customer demand for scalable spatial; consumables-led growth; opex discipline / path to profitability; "evolving the company to drive growth at scale".
• Tone shift over the last ~18 months: the narrative has migrated from defensive (2023-24: macro headwinds, China de-stocking, NIH uncertainty, litigation overhang, deep losses) toward cautiously offensive (2025-26: consumables inflection, margin expansion, settlements monetized into cash + royalties, a flagship product launch). The single most important new phrase is "moderately increase in 2026" — management's own framing that ex-settlement revenue resumes growth.
• What they stopped saying: the acute China-distributor-destocking language that dominated 2023 calls has faded; the litigation discussion has shifted from "defending" Vizgen/Bruker to "we settled and now collect royalties" — and pivoted to 10x as plaintiff against Illumina.
• The honest tension on the call: strong consumables + margin, undercut by the admission that Q2/Q3 step down and instruments stay weak — analysts pressed on Atera cannibalization and funding variability.

Lens 7 · Comps

Single-cell/spatial-tools peer set. Multiples are `` with source/date or n/a. I did not fabricate any multiple.

Read on the one multiple I can source: at ~5.6x sales (vs Simply Wall St's "fair" ~4.7x), TXG screens expensive on sales for a 0-4% grower — the multiple is paying for the consumables-acceleration option and the eventual operating-leverage flip to GAAP profit, not for current growth. A loss-making 0-4% grower at 5.6x sales only works if (a) consumables re-accelerate to double digits durably and (b) the opex discipline converts to real free cash flow. Peer multiples not sourced here are the single biggest gap in this dossier — a proper relative-value call needs ILMN/BRKR/QGEN EV/Sales pulled before sizing a position.

Lens 8 · Stock-Price Catalysts (what actually moves TXG)

Pattern over the cycle, ``-sourced:

• The 2026 melt-up: +73.5% YTD, ~+187% off the $10.17 low to ~$29; 52-wk high $35.65. Driver = consumables-inflection narrative + opex turn + heavy short interest (14.5% of float ) fueling squeeze dynamics.
• Earnings are the dominant catalyst, and the quality of the reaction is counter-intuitive: Q1 2026 beat and the stock fell 5-8%; a late-2025 print + bank downgrades produced a ~20% weekly drop. The market reacts to forward guide and instrument trajectory, not the consumable beat.
• Partnership / clinical-translation headlines move it: a Cleveland Clinic bladder-cancer research agreement popped the stock ~4%; AACR/AGBT product unveilings (Atera) are catalysts.
• Litigation milestones are episodic catalysts (settlement announcements = positive; PTAB/IPR losses = negative).
• Macro/policy: NIH-funding headlines and academic-budget policy are a sector-wide beta 10x carries acutely (US ~53% of revenue, academic-skewed).

What the pattern reveals: TXG trades as a high-beta, heavily-shorted narrative-and-guidance stock, not a numbers-in-line stock. The asymmetry right now is unfavorable into a quarter management has pre-guided lower.

---

Phase C — Judge people & books

Lens 9 · Management

• Track record. Serge Saxonov (co-founder, CEO since 2012, ~13.6-yr tenure) and Ben Hindson (co-founder, President & CSO) built the single-cell category essentially from scratch — Chromium defined the market, then they extended into spatial (Visium → Xenium → Atera) partly organically, partly via tuck-in M&A. Genuinely founder-led, deeply scientific (most of senior management and the board hold PhDs).
• Skin in the game. Saxonov owns 3.27% ($78M) — meaningful founder alignment. Total comp ~$7.9M, ~92% equity/bonus-weighted.
• Capital-allocation history — mixed. Pro: disciplined opex reset in 2025-26 (R&D −10%, SG&A −8% FY25; total opex −15% Q1'26), zero debt, ~$510M cash hoard, no value-destroying leverage. Con: a decade of losses, $1.5B accumulated deficit, ROE persistently negative; serial acquirer (two deals in 2018, two in 2020, one each 2021/2023/2025 — Scale Bio in Aug 2025 with up to $30M contingent earn-out) whose returns are unproven. The 2023 $61M in-process-R&D write-off (Centrillion-related) is a reminder that not every tuck-in pays off.
• Recent leadership refresh: new CFO Adam Taich (ex-Standard BioTools) and CCO Mennah Moustafa — a deliberate go-to-market and finance upgrade as the company shifts from hyper-growth to "growth at scale".
• Comp alignment (a genuine positive): the 2026 PSU grants tie 50% to revenue CAGR (2026-27) and 50% to relative TSR vs the Russell 3000 Medical Equipment & Services index (2026-28) — and management deemed the revenue-CAGR component "not probable" of vesting as of Q1 2026, i.e. they are not even booking expense for it. That is an honest, demanding bar, not a layup.
• Red flags (Lens-9 level): insider selling has been flagged during the 2026 run — normal for founders diversifying into strength, but worth watching. Founder archetype = mission-driven scientist-CEO; the risk of that archetype here is over-investing in technically dazzling platforms (Atera) ahead of customers' willingness to pay in a budget-constrained funding environment.

Lens 10 · Forensic Red Flags

Accounting-quality read: clean-to-conservative on the core statements; the real "forensic" story is that revenue quality was temporarily flattered by non-recurring settlement items — which management itself disclosed and quantified.

• Revenue recognition / non-recurring revenue (the one thing to watch). FY2025's +5% headline embeds $46.1M of license/royalty revenue + $49.9M of "gain on settlement" from the Vizgen and Bruker patent settlements. Management is transparent: it states ex the $44.1M of non-recurring 2025 settlement revenue, it "expects revenues to moderately increase in 2026". Not a red flag in the deceptive sense — it's disclosed — but it means any naive YoY comparison overstates the business. The Bruker structure (4 quarterly installments totaling $68M; $34M still receivable at year-end, in "Other receivables" which jumped to $35.5M from $0.6M) is the line to track.
• Cash flow vs earnings. OCF $136.1M on a $43.5M net loss looks great — but $109.1M of it is stock-based-comp add-back (17% of revenue), plus the $60M of settlement cash collected in-period. SBC running at ~17% of revenue (Q1'26 $22.6M) is the single biggest "non-GAAP flatters reality" item — real economic dilution masquerading as a non-cash add-back.
• Receivables / inventory. Both moved the right way: AR fell to $47.0M (from $87.9M) on collection timing; inventory fell to $53.5M. No receivables-outrunning-revenue or inventory-build red flag.
• Goodwill / intangibles. Tiny goodwill ($4.5M); intangibles jumped to $62.3M on the Scale Bio asset acquisition (developed technology $52.6M) — watch for future impairment if Scale Bio's tech under-delivers (there was already a small ROU-asset impairment on the acquired Scale Bio facility).
• SBC / dilution. Class A 118.9M + Class B 10.1M = ~129.0M shares; 11.6M anti-dilutive equivalents (RSUs 8.0M, options 3.4M) excluded from the loss-per-share denominator. Dilution is the persistent shareholder tax.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: none. regulatory/regulatory-findings.md (EDGAR EFTS, LR + AAER, 2021-06-24 → 2026-06-24) returned 0 SEC findings.
• Non-SEC enforcement (web search "10x Genomics" + FTC/DOJ/FDA/penalty): no material government enforcement actions surfaced. 10x's legal footprint is offensive patent litigation it initiates, not enforcement against it.
• Item 3 / Legal Proceedings (from the filings) — material and central to the thesis:
• Parse Biosciences (10x as plaintiff, single-cell): consent judgment + permanent injunction won on ATAC-seq patents (Feb 2025); but three asserted 10x patents (981/197/013) found unpatentable at the PTAB (Feb 2025), on appeal; litigation stayed pending appeal. Scale Bio↔Parse cross-suit trial set Aug 2026 (mixed interim rulings — a 10x/Scale patent ruled invalid Oct 2025, on appeal). Note: QIAGEN has since acquired Parse.
• Curio Bioscience (spatial): UPC granted 10x a permanent injunction (Germany/France/Sweden, June 2025); US trial set May 2026.
• Illumina (the big one): two suits filed Oct 2025 — spatial (10x + Prognosys, 4 patents) and single-cell (10x + Roche, 5 patents); trials set Jan 2028 (spatial) and Apr 2028 (single-cell).
• Element Biosciences (with Harvard, multiomics) — additional offensive suit.
• 10x has concluded a loss is not probable and recorded no contingent liability as of 2026-03-31.

Bottom line on books: I'd grade accounting quality B+ / clean — the only asterisk is the settlement-inflated 2025 optics (disclosed) and chronic ~17%-of-revenue SBC. The litigation is a strategic, double-edged feature, not an accounting risk.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (FY2026 → FY2028 EPS)

Framework, fully labeled. Output is ``; no forecast.ts logged (watchlist rule). 10x is GAAP-loss-making, so the meaningful projection is the path to GAAP breakeven, not a positive-EPS multiple.

Base inputs: FY2025 product+services revenue $596.7M; FY2026 company guide $600-625M total (= 0-4% ex-settlement); gross margin ~69-70%; FY2025 total opex ex-settlement-gain ~$554.8M ($504.9M reported + $49.9M gain add-back); ~129M shares, growing ~2-3%/yr on SBC; ~$510M cash earning ~$20M/yr interest income.

The one number that matters: at the base case, 10x reaches GAAP breakeven around FY2028 — which means at ~$29 the stock is already discounting the bull path (a profitable, double-digit-growing spatial leader), because there is no positive GAAP EPS to anchor a P/E in the base case until then. Cash runway is a non-issue — $510M cash, FCF-positive ex-settlement-ish, capex guided to only $15-20M/yr — so this is not a financing-risk story; it's a valuation-vs-execution story.

Brier forecast NOT logged (watchlist-loop rule). If promoted to a thesis, the scoreable line is: "TXG FY2028 reaches GAAP operating breakeven or better, p≈0.55."

Lens 12 · Bull vs Bear

Bull case. The consumables annuity has inflected and is the highest-quality revenue in tools: Q1'26 consumables +13%, spatial consumables +31%, single-cell consumables back to +6% — a maturing 8,046-instrument base finally pulling through. Gross margin 70% and rising; opex cut 15% with legal overhang lifting → a credible operating-leverage flip to GAAP profitability by ~FY2028. The Vizgen/Bruker settlements converted a cost center into a royalty stream + $510M cash war-chest, zero debt. Atera ($495K, whole-transcriptome spatial) extends the franchise and reloads instrument growth into 2027. Secular tailwind intact: single-cell market ~$4.5B→$12.6B (14% CAGR), spatial $0.64B→$2.1B (13% CAGR). And 10x is winning its IP wars (Curio/Parse injunctions), wielding the patent estate as offense.

Bear case (permanent-impairment risks).

1. Illumina enters spatial with vastly superior scale and balance sheet. If Illumina's spatial platform (claimed 9x capture area) wins on the installed sequencing base, 10x's spatial growth engine — the entire bull thesis — is capped, and the IP suits (trials not until 2028) won't save the near term.
2. Atera cannibalizes the Xenium installed base 10x just built. Management pre-guided Q2/Q3 down on customers pausing Xenium buys for Atera; if labs "just landed a machine" won't spend another $500K in a tight-funding environment, spatial instrument revenue stays impaired and consumable pull-through stalls.
3. Structural US academic/NIH funding compression. US revenue −12% YoY; the academic-skewed, ~53%-US base is exposed to a multi-year research-budget downcycle no execution can fully offset.

Pre-mortem (18 months out, thesis broke): It's late 2027. The stock round-tripped from $29 back toward the mid-teens. What happened: Atera shipped but cannibalized more Xenium than it added; spatial consumable growth decelerated to high-single-digits; Illumina's spatial product took the marginal new lab; US funding stayed soft through two budget cycles; the +73% 2026 melt-up was a short-squeeze (14.5% float short) that unwound; and GAAP breakeven slipped to FY2029. The 5.6x sales multiple compressed to ~3x on a 0-5% grower.

Are multiples too high? For a 0-4% grower with no GAAP earnings, 5.6x sales is rich — it prices the bull path. The market is currently refusing to see (contrarian view): that the consumables inflection might be real and durable enough that the right comparison isn't "expensive 0% grower" but "early-innings operating-leverage story where the consumable annuity reprices to a much higher multiple once GAAP profit appears." The bull's contrarian edge is time arbitrage on the leverage flip; the bear's contrarian edge is the squeeze already happened.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• The +73% YTD move is substantially mechanical, not fundamental. 14.5% of float short into a consumables-beat narrative = textbook squeeze fuel. Strip the squeeze and you have a 0-4% grower that missed nothing but guided down.
• Revenue concentration shift = the funding cliff. ~53% US, academic-skewed. If NIH/academic budgets compress structurally, the demand base doesn't rotate — it shrinks. EMEA/APAC-ex-China growth is too small to offset a US air-pocket.
• The moat is weaker than bulls think on the growth flank. The single-cell patents that built the moat are getting invalidated at the PTAB (3 patents, on appeal); the spatial moat faces Illumina, a competitor with ~10x the resources and the sequencing install base. A company that needs five simultaneous lawsuits (Parse, Curio, Illumina ×2, Element) to defend its position is signaling the technology moat alone isn't holding.
• Most dangerous competitor bulls underestimate: Illumina — not because Illumina's spatial tech is necessarily better, but because it can bundle spatial into existing sequencer relationships and outspend 10x on commercialization indefinitely.
• Worst capital-allocation tell: a decade of losses, $1.5B accumulated deficit, ~17%-of-revenue SBC, and a serial-acquisition habit (Scale Bio's contingent earn-out, the 2023 $61M IPR&D write-off) with no proven inorganic ROI.
• What must hold for $29: consumables sustain double-digit growth and opex stays flat and Atera adds-not-cannibalizes and US funding stabilizes and GAAP profit arrives by FY2028. That's five things, into a quarter pre-guided lower.
• Down-20-30% growth scenario: if FY2027 revenue growth is +3% instead of +10%, GAAP breakeven slips past FY2029, and 5.6x sales compresses toward the ~3-4x where un-profitable, slow-growing tools names trade → a stock in the mid-teens, ~40-50% downside.
• Single permanent-impairment scenario: Illumina wins meaningful spatial share AND the PTAB invalidations stand on appeal → 10x is a single-cell legacy annuity in slow decline with a failed spatial growth bet. Plausibility: moderate (~25-30%).

Lens 14 · Management Questions (ordered by information value)

1. Ex-settlement, what is your honest internal expectation for 2026 consumables growth specifically — and does the Q2/Q3 sequential step-down reflect only Atera timing, or underlying spatial-consumable deceleration?
2. Atera vs. Xenium: what is your evidence that Atera is net additive to the installed base rather than cannibalizing Xenium pull-through, and what's the expected payback period for a customer's $495K spend in this funding environment?
3. On Illumina's spatial entry — beyond litigation, how do you defend share commercially against a competitor that can bundle spatial into existing sequencer relationships?
4. If the PTAB invalidations of the 981/197/013 patents are upheld on appeal, how much of your single-cell competitive position is actually patent-protected versus process/scale-protected?
5. What % of revenue is exposed to US academic/NIH funding, and what is your contingency if that base compresses for 2-3 more years?
6. When do you expect sustained GAAP operating profitability, and what revenue level does that require at current gross margin?
7. SBC is ~17% of revenue — what is the multi-year plan to bring it down, and how do you think about real dilution to long-term holders?
8. Capital allocation: with $510M and zero debt, why not a buyback to offset SBC dilution rather than more tuck-in M&A — and what is the realized ROI on Scale Bio so far?
9. Instrument placements fell 39% in 2025 — at what point does a shrinking instrument base threaten the future consumable annuity, and what's the leading indicator you watch?
10. China is −6% on top of years of decline — is there a viable China strategy, or do you now model it as a structural runoff?
11. What is the realistic timeline and economics for clinical/translational adoption (e.g., the Cleveland Clinic bladder-cancer work) — is clinical a 2027 revenue driver or a 2030 story?
12. How should we think about the Bruker royalty stream durability and the remaining $34M receivable — and are further monetizable IP settlements in the pipeline?
13. Gross margin hit 70% — is that a new floor, or did one-time inventory-write-down relief flatter it, and where does structural GM settle?
14. With a new CFO and CCO, what specifically changes in go-to-market and financial discipline over the next 4 quarters?
15. What is the one assumption embedded in your plan that, if wrong, would most damage the 3-year thesis?

---